![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma
European Commission Approves Takeda’s Adcetris for Large-Cell Lymphoma
May 15, 2020
The European Commission has approved Takeda’s Adcetris (brentuximab vedotin) as an adjunct treatment for adult patients with previously untreated systemic anaplastic large-cell lymphoma (sALCL).
The approval was based on the results of a phase 3 trial in which Adcetris plus cyclophosphamide, doxorubicin and prednisone demonstrated significant improvement in progression-free survival.
Adcetris is approved in the U.S. for several indications, including sALCL.
Upcoming Events
-
21Oct